Cost-effectiveness of peginterferon alpha-2a and peginterferon alpha-2b combination regimens in genotype-1 naive patients with chronic hepatitis C.
Gheorghe
Liana
L
Center of Gastroenterology & Hepatology, Fundeni Clinical Institute of Digestive Diseases & Liver Transplantation, Fundeni street, 253 Bucharest, Romania. drgheorghe@xnet.ro
Baculea
Simona
S
D000998:Antiviral Agents / Q000008:administration & dosage* / Q000191:economics; D003362:Cost-Benefit Analysis; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000191:economics*; D008390:Markov Chains; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000191:economics*; D019057:Quality-Adjusted Life Years; D011994:Recombinant Proteins; D012383:Romania; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a